Omicron
An early study of vaccine effectiveness showed that the shots from AstraZeneca Plc and the Pfizer Inc.-BioNTech SE partnership provided much lower defenses against symptomatic infection with omicron, compared with the delta strain, after two doses. A booster lifted protection to 70% to 75% in the early days after the shot
( Read more... )
Comments 1
Reply
Leave a comment